Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
AssigneeAmarin Pharmaceuticals Ireland Limited
InventorsRene Braeckman, William Stirtan, Paresh Soni
Life of this patent
Estimating the term…
Abstract
In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
Claims24
A method of lowering triglycerides and a fatty acid desaturation index (“FADI”) associated with a subject on statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising determining a baseline FADI level associated with the subject;
- and thereafter administering to the subject a pharmaceutical composition comprising about 4 grams per day of ethyl eicosapentaenoate to effect a reduction in triglycerides and the FADI associated with the subject.
A method of lowering triglycerides, LDL-C and a fatty acid desaturation index (“FADI”) associated with a subject having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl who is on stable statin therapy, the method comprising determining a baseline FADI level associated with the subject and thereafter administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 90%, by weight of all fatty acids present, ethyl eicosapentaenoate for a period of at least about 12 weeks to effect a reduction in triglycerides, LDL-C, and the FADI associated with the subject.
A method of lowering a fatty acid desaturation index (“FADI”) associated with a subject having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl who is on stable statin therapy, the method comprising determining a baseline FADI associated with the subject and thereafter administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 90%, by weight of all fatty acids present, ethyl eicosapentaenoate for a period of at least about 12 weeks.
A method of lowering a fatty acid desaturation index (“FADI”) associated with a subject on statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl, the method comprising determining a baseline FADI associated with the subject and thereafter administering to the subject a pharmaceutical composition comprising about 4 g per day of ethyl eicosapentaenoate.
Dependencies are inferred from the claim text.